NCT05746208 2026-03-17
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
University of California, San Francisco
Phase 2 Recruiting
Clinical Trials
52 trialsNCT07092514 2026-03-17
Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
Washington University School of Medicine
Phase 2 Recruiting
NCT06859684 2026-03-09
HAIC-quad
West China Hospital
Phase 2 Recruiting
NCT05775159 2026-02-18
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
AstraZeneca
Phase 2 Recruiting
NCT06669572 2026-02-17
Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment
University of Chicago
Phase 2 Recruiting
NCT07389629 2026-02-05
Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Sun Yat-sen University
Phase 2 Recruiting
NCT07359053 2026-01-22
MAGNATE-S
Shanghai 6th People's Hospital
Phase 2 Recruiting
NCT05327686 2026-01-14
SAMURAI
NRG Oncology
Phase 2 Recruiting
NCT05286437 2025-12-30
LaPemERLA
National Cancer Centre, Singapore
Phase 2 Recruiting
NCT07081633 2025-12-30
TREMENDOUS-2
AstraZeneca
Phase 2 Recruiting
NCT06266338 2025-12-22
Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
University of Texas Southwestern Medical Center
Phase 2 Recruiting
NCT06880523 2025-12-18
SLIDE-HCC
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT07282262 2025-12-15
An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT06230471 2025-12-09
Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT07157969 2025-12-01
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT04887805 2025-11-19
Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer
City of Hope Medical Center
Phase 2 Recruiting
NCT06962787 2025-11-17
A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT05064280 2025-10-09
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05168163 2025-09-16
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
Academic and Community Cancer Research United
Phase 2 Recruiting
NCT05903833 2025-09-09
PIERCE
AGO Research GmbH
Phase 2 Recruiting
NCT06374602 2025-09-05
Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer
Saint Petersburg State University, Russia
Phase 2 Recruiting
NCT07070700 2025-08-12
CASTLE-ZS-02
Fudan University
Phase 2 Recruiting
NCT05181033 2025-07-25
Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor
National University Hospital, Singapore
Phase 2 Recruiting
NCT06892925 2025-07-10
Spring
Eastern Hepatobiliary Surgery Hospital
Phase 2 Recruiting
NCT07047586 2025-07-03
LEAF-01
Fudan University
Phase 2 Recruiting
NCT06157996 2025-05-30
Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore
Nanfang Hospital, Southern Medical University
Phase 2 Recruiting
NCT06318286 2025-05-25
PENINSULA
Hyogo Medical University
Phase 2 Recruiting
NCT06420440 2025-05-01
Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model
Tongji Hospital
Phase 2 Recruiting
NCT06904196 2025-04-29
Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Recruiting
NCT03899428 2025-03-24
Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC
Humanity & Health Medical Group Limited
Phase 2 Recruiting
NCT06208462 2025-03-03
Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT05010681 2025-02-27
Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer
Fudan University
Phase 2 Recruiting
NCT05098847 2025-02-27
Cryoablation Combined with Sintilimab Plus Lenvatinib in Previously Treated Unresectable Liver Metastasis from Solid Tumors
Fudan University
Phase 2 Recruiting
NCT06032845 2025-02-27
CASTLE-11
Fudan University
Phase 2 Recruiting
NCT05920863 2025-02-11
Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors
Zhejiang Cancer Hospital
Phase 2 Recruiting
NCT05532059 2025-02-10
Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT05103904 2024-12-27
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
Emory University
Phase 2 Recruiting
NCT06739395 2024-12-18
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
Tianjin Medical University Second Hospital
Phase 2 Recruiting
NCT06187961 2024-12-12
CCGLC-011
Tongji Hospital
Phase 2 Recruiting
NCT05185739 2024-12-06
PRIMER-1
University College, London
Phase 2 Recruiting
NCT06482086 2024-12-05
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
West China Hospital
Phase 2 Recruiting
NCT06192797 2024-11-05
CCGLC-013
Tongji Hospital
Phase 2 Recruiting
NCT04951947 2024-09-19
JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer
Hunan Province Tumor Hospital
Phase 2 Recruiting
NCT06298968 2024-07-03
Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma
Nanfang Hospital, Southern Medical University
Phase 2 Recruiting
NCT04803318 2024-06-25
Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Recruiting
NCT06406634 2024-05-09
Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma
Hunan Cancer Hospital
Phase 2 Recruiting
NCT06383559 2024-04-25
Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT06261125 2024-03-12
HSBRT2401
Sun Yat-sen University
Phase 2 Recruiting
NCT05832827 2023-10-23
Artemis
National Cancer Center, Japan
Phase 2 Recruiting
NCT05992584 2023-09-14
Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Recruiting